Table 5.
Percentage of cohort participants reporting side effects by molecule by survey month.
| Side effect | Month 1, n (%) | Month 3, n (%) | Month 6, n (%) | Month 12, n (%) | ||||
|
|
Tirzepatide cohort (n=209) | Semaglutide cohort (n=130) | Tirzepatide cohort (n=209) | Semaglutide cohort (n=130) | Tirzepatide cohort (n=209) | Semaglutide cohort (n=130) | Tirzepatide cohort (n=209) | Semaglutide cohort (n=130) |
| Constipation | 61 (29.2) | 41 (31.5) | 45 (21.5) | 40 (30.8) | 42 (20.1) | 23 (17.7) | 27 (12.9)a | 20 (15.4) |
| Diarrhea | 18 (8.6) | 13 (10) | 20 (9.6) | 14 (10.8) | 26 (12.4) | 7 (5.4) | 13 (6.2) | 7 (5.4) |
| Feeling anxious | 5 (2.4) | 2 (1.5) | 4 (1.9) | 1 (0.8) | 1 (0.5) | 3 (2.3) | 4 (1.9) | 1 (0.8) |
| Feeling dizzy | 12 (5.7) | 6 (4.6) | 7 (3.3) | 5 (3.8) | 2 (1) | 2 (1.5) | 6 (2.9) | 5 (3.8) |
| Feeling more tired than usual | 45 (21.5) | 32 (24.6) | 42 (20.1) | 26 (20) | 29 (13.9) | 23 (17.7) | 17 (8.1)b | 4 (3.1)b |
| Feeling sick | 58 (27.8) | 41 (31.5) | 59 (28.2) | 46 (35.4) | 42 (20.1) | 14 (10.8)b | 22 (10.5)b | 4 (3.1)b |
| Hair loss | 3 (1.4) | 2 (1.5) | 6 (2.9) | 1 (0.8) | 22 (10.5)b | 4 (3.1) | 20 (9.6)b | 7 (5.4) |
| Headaches | 16 (7.7) | 20 (15.4) | 9 (4.3) | 18 (13.8) | 5 (2.4) | 3 (2.3)b | 5 (2.4) | 3 (2.3)b |
| Heartburn or indigestion | 37 (17.7) | 11 (8.5) | 37 (17.7) | 27 (20.8) | 21 (10) | 11 (8.5) | 10 (4.8)b | 7 (5.4) |
| No side effects | 87 (41.6) | 70 (53.8) | 82 (39.2) | 41 (31.5)b | 92 (44) | 70 (53.8) | 126 (60.3)b | 88 (67.7) |
| None of the above | 4 (1.9) | 3 (2.3) | 4 (1.9) | 1 (0.8) | 4 (1.9) | 3 (2.3) | 5 (2.4) | 2 (1.5) |
| Reactions in the injection site | 10 (4.8) | 2 (1.5) | 12 (5.7) | 0 (0) | 25 (12) | 1 (0.8) | 11 (5.3) | 2 (1.5) |
| Severe stomach pain | 0 (0) | 1 (0.8) | 0 (0) | 1 (0.8) | 1 (0.5) | 1 (0.8) | 0 (0) | 1 (0.8) |
| Tender or swollen stomach | 2 (1) | 1 (0.8) | 1 (0.5) | 2 (1.5) | 2 (1) | 1 (0.8) | 0 (0) | 0 (0) |
| Vomiting | 5 (2.4) | 2 (1.5) | 10 (4.8) | 7 (5.4) | 6 (2.9) | 3 (2.3) | 5 (2.4) | 1 (0.8) |
aP=.002.
bP<.001.